Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryJul 31, 2014	Xencor Reports Second Quarter 2014 Financial Results Conference call today at 4:30 p.m. EDT	View HTML Xencor Reports Second Quarter 2014 Financial Results 29.1 KB
Toggle SummaryJul 24, 2014	Xencor to Host Second Quarter 2014 Financial Results Webcast and Conference Call MONROVIA, Calif. , July 24, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that it will release second quarter	View HTML Xencor to Host Second Quarter 2014 Financial Results Webcast and Conference Call 12.7 KB
Toggle SummaryJul 15, 2014	Xencor Appoints Kurt Gustafson to Board of Directors; Promotes John Desjarlais to Chief Scientific Officer MONROVIA, Calif. , July 15, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced the appointment of Kurt Gustafson	View HTML Xencor Appoints Kurt Gustafson to Board of Directors; Promotes John Desjarlais to Chief Scientific Officer 15.8 KB
Toggle SummaryMay 28, 2014	Xencor Initiates Phase 1 Study of XmAb7195 for Asthma MONROVIA, Calif. , May 28, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that the first subject has been	View HTML Xencor Initiates Phase 1 Study of XmAb7195 for Asthma 64.9 KB
Toggle SummaryMay 22, 2014	Xencor to Present at Jefferies 2014 Global Healthcare Conference MONROVIA, Calif. , May 22, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that Bassil Dahiyat , Ph.D.,	View HTML Xencor to Present at Jefferies 2014 Global Healthcare Conference 12.6 KB
Toggle SummaryMay 15, 2014	Xencor Presents Study Comparing XmAb7195 to Omalizumab at the American Thoracic Society 2014 International Conference Rapid IgE clearance by XmAb7195 shows potential as a disease modifying treatment for allergy and asthma	View HTML Xencor Presents Study Comparing XmAb7195 to Omalizumab at the American Thoracic Society 2014 International Conference 103.3 KB
Toggle SummaryMay 14, 2014	Xencor Reports First Quarter 2014 Financial Results Conference call today at 4:30 p.m. EDT	View HTML Xencor Reports First Quarter 2014 Financial Results 24.1 KB
Toggle SummaryMay 07, 2014	Xencor to Host First Quarter 2014 Financial Results Webcast and Conference Call MONROVIA, Calif. , May 7, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that it will release first quarter	View HTML Xencor to Host First Quarter 2014 Financial Results Webcast and Conference Call 12.7 KB
Toggle SummaryApr 29, 2014	Xencor, Inc. to Present at Deutsche Bank 39th Annual Health Care Conference MONROVIA, Calif. , April 29, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that Bassil Dahiyat , Ph.D.,	View HTML Xencor, Inc. to Present at Deutsche Bank 39th Annual Health Care Conference 12.6 KB
Toggle SummaryApr 10, 2014	Xencor Receives Milestone Payment from Merck for Initiation of Phase 1 Clinical Trial of a Biologic Candidate using XmAb® Antibody Engineering Intellectual Property MONROVIA, Calif. , April 10, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that the company has received a	View HTML Xencor Receives Milestone Payment from Merck for Initiation of Phase 1 Clinical Trial of a Biologic Candidate using XmAb® Antibody Engineering Intellectual Property 15.6 KB

Tools

Press Releases